CRH Medical - 500 Beiträge pro Seite
eröffnet am 05.08.16 14:23:38 von
neuester Beitrag 09.04.19 22:10:16 von
neuester Beitrag 09.04.19 22:10:16 von
Beiträge: 23
ID: 1.236.376
ID: 1.236.376
Aufrufe heute: 0
Gesamt: 504
Gesamt: 504
Aktive User: 0
ISIN: CA12626F1053 · WKN: A0YJG3
3,9950
USD
+0,13 %
+0,0050 USD
Letzter Kurs 23.04.21 Nasdaq
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +25,00 | |
| 9,5000 | +18,75 | |
| 0,6400 | +18,52 | |
| 0,6850 | +17,40 | |
| 0,9060 | +14,83 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8410 | -17,06 | |
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Feedback
...betreibt Anästhesie-Abteilungen in Arztpraxen als Service;
scheinen eine buy-and-build Strategie zu verfolgen;
hierüber drauf gekommen:
scheinen eine buy-and-build Strategie zu verfolgen;
hierüber drauf gekommen:
Antwort auf Beitrag Nr.: 52.997.971 von R-BgO am 05.08.16 14:25:13zu CAD $ 4,95 ausgeführt
Antwort auf Beitrag Nr.: 52.998.808 von R-BgO am 05.08.16 15:44:14
marschiert wie verrückt,
schon 60% im Plus...
Antwort auf Beitrag Nr.: 53.737.230 von R-BgO am 21.11.16 10:13:12wie ein Fahrtstuhl, erster Verdoppler
Trading Spotlight
CRH Medical Corporation Announces Acquisition in Florida and First Monitored Anesthesia Care Development Program in Washington State
VANCOUVER, B.C. – March 15, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), announces that it has completed an accretive transaction whereby CRH has acquired a 60% interest in a gastroenterology (“GI”) anesthesia practice in Kissimmee Florida (“Kissimmee”).
CRH also announces that it has entered into an exclusive agreement to develop and manage a monitored anesthesia care (“MAC”, or “Deep Sedation”) program with Puget Sound Gastroenterology (“PSG”), located in Washington State. Under the terms of the agreement, CRH has the option to acquire 51% of the newly created MAC business at a future date.
Kissimmee Transaction Highlights
Total annual estimated revenue of US$2.2 million
EBITDA and cash flow accretive
Services one ambulatory surgical center (“ASC”) and is CRH’s third acquisition in Florida
Structured as joint venture with CRH retaining a 60% interest
PSG Transaction Highlights
PSG is a premier group of gastroenterologists with four ASCs in the greater Seattle area
CRH to develop and manage an MAC program for PSG
CRH retains an option to purchase 51% of the new anesthesia business at a future date, no sooner than 12 months
CRH estimates that approximately half of the endoscopic procedures administered in ASCs are performed without MAC, the standard of care for anesthesia for endoscopic procedures. CRH’s MAC Development Program represents a significant new opportunity to expand the Company’s anesthesia services business by employing its expertise to assist gastroenterology practices to transition to monitored anesthesia for better patient care.
Edward Wright, CEO of CRH, stated, "The Kissimmee transaction with an existing O’Regan customer expands our anesthesia presence to 27 ASCs. More importantly, the MAC program will contribute greatly to CRH’s long-term shareholder value and is a significant new opportunity to engage gastroenterologists currently not utilizing Deep Sedation, which may be as much as 50% of the GI market. Under the MAC program, CRH has the option to purchase 51% of PSG’s anesthesia business after 12 months. Until such time, we will not recognize any material revenue or expense from PSG.”
VANCOUVER, B.C. – March 15, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), announces that it has completed an accretive transaction whereby CRH has acquired a 60% interest in a gastroenterology (“GI”) anesthesia practice in Kissimmee Florida (“Kissimmee”).
CRH also announces that it has entered into an exclusive agreement to develop and manage a monitored anesthesia care (“MAC”, or “Deep Sedation”) program with Puget Sound Gastroenterology (“PSG”), located in Washington State. Under the terms of the agreement, CRH has the option to acquire 51% of the newly created MAC business at a future date.
Kissimmee Transaction Highlights
Total annual estimated revenue of US$2.2 million
EBITDA and cash flow accretive
Services one ambulatory surgical center (“ASC”) and is CRH’s third acquisition in Florida
Structured as joint venture with CRH retaining a 60% interest
PSG Transaction Highlights
PSG is a premier group of gastroenterologists with four ASCs in the greater Seattle area
CRH to develop and manage an MAC program for PSG
CRH retains an option to purchase 51% of the new anesthesia business at a future date, no sooner than 12 months
CRH estimates that approximately half of the endoscopic procedures administered in ASCs are performed without MAC, the standard of care for anesthesia for endoscopic procedures. CRH’s MAC Development Program represents a significant new opportunity to expand the Company’s anesthesia services business by employing its expertise to assist gastroenterology practices to transition to monitored anesthesia for better patient care.
Edward Wright, CEO of CRH, stated, "The Kissimmee transaction with an existing O’Regan customer expands our anesthesia presence to 27 ASCs. More importantly, the MAC program will contribute greatly to CRH’s long-term shareholder value and is a significant new opportunity to engage gastroenterologists currently not utilizing Deep Sedation, which may be as much as 50% of the GI market. Under the MAC program, CRH has the option to purchase 51% of PSG’s anesthesia business after 12 months. Until such time, we will not recognize any material revenue or expense from PSG.”
aus einem Letter von Alluvial Capital:
Finally, CRH Medical. This anesthesiology practice roll-up was a strong contributor to returns in the first quarter, and a large detractor since! After shares marched from under $4 to over $9 in just a few months, shares plunged to below $6 on the heels of a critical write-up by a Canadian fund manager.
In his letter, the manager leveled several accusations against the company, accusing them of using aggressive billing practices and claiming that reimbursement rates for anesthesiology procedures were sure to decline.
Management defended the company patiently but vigorously in the quarterly earnings call, carefully explaining how their billing and staffing practices are industry standard and that they have never had any pushback from insurers.
Management also laid out the case for why current reimbursement rates would not be reduced substantially, arguing that both the government and private insurers are strongly incentivized to encourage colonoscopies and early colon cancer detection.
While I was satisfied with management’s explanations, the market clearly has its doubts. It may take some time for confidence in the company to return, but I do not believe the uncertainty will have any serious impact on CRH Medical’s efforts to add new practices and grow its cash flow.
Currently, CRH Medical’s normalized free cash flow yield is around 8%, a level I believe is very attractive given the company’s ability to invest substantial additional capital at high rates.
CRH Medical Corporation Comments on the Centers for Medicare and Medicaid Services 2018 Proposed Fee Schedule
VANCOUVER, B.C. – July 17, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”) commented on the estimated impact of the Center for Medicare and Medicaid Services (“CMS”) proposed fee schedule (the “Proposed Rule”) for 2018.
The CMS 2018 Medicare Physician Fee Schedule Proposed Rule was announced on July 13, 2017 and updates payment policies, payment rates, and other provisions for services furnished under the Medicare Physician Fee Schedule on or after January 1, 2018.
The Proposed Rule changes the billing structure for CRH’s primary billing code for anesthesia provided in conjunction with a lower endoscopy by eliminating the existing billing code and replacing them with two new billing codes. The new billing codes will have the net effect of decreasing the amount CRH will likely bill and collect for anesthesia services provided in conjunction with a lower endoscopy. At this point, the Company expects that the new billing codes will be adopted by all commercial and federal payors effective January 1, 2018.
The Company has analyzed the impact of the new codes on its business and has determined that if the new codes were implemented today as currently proposed, anesthesia revenue would decrease by approximately 8.5% and total revenue would decrease by approximately 7.5%. In addition, our total adjusted operating EBITDA(1) would decrease by approximately 13.5%. We believe that this would decrease our total adjusted operating EBITDA(1) margin from 53% to approximately 47%.
(1) Adjusted operating EBITDA: This is a non-IFRS measure defined as operating income before interest, taxes, depreciation, amortization, stock based compensation, acquisition related expenses and asset impairment charges. Refer to the end of this document for the reconciliation of reported financial results to non-IFRS measures.
Edward Wright, Chief Executive Officer, commented, “If the new billing codes go into effect as currently proposed, we anticipate that our business will continue to generate strong adjusted operating EBITDA margins of approximately 47%. Our focus continues to be growing our business through acquisitions and organic growth, which will be funded from our cash flow from operations and existing credit facility.”
VANCOUVER, B.C. – July 17, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”) commented on the estimated impact of the Center for Medicare and Medicaid Services (“CMS”) proposed fee schedule (the “Proposed Rule”) for 2018.
The CMS 2018 Medicare Physician Fee Schedule Proposed Rule was announced on July 13, 2017 and updates payment policies, payment rates, and other provisions for services furnished under the Medicare Physician Fee Schedule on or after January 1, 2018.
The Proposed Rule changes the billing structure for CRH’s primary billing code for anesthesia provided in conjunction with a lower endoscopy by eliminating the existing billing code and replacing them with two new billing codes. The new billing codes will have the net effect of decreasing the amount CRH will likely bill and collect for anesthesia services provided in conjunction with a lower endoscopy. At this point, the Company expects that the new billing codes will be adopted by all commercial and federal payors effective January 1, 2018.
The Company has analyzed the impact of the new codes on its business and has determined that if the new codes were implemented today as currently proposed, anesthesia revenue would decrease by approximately 8.5% and total revenue would decrease by approximately 7.5%. In addition, our total adjusted operating EBITDA(1) would decrease by approximately 13.5%. We believe that this would decrease our total adjusted operating EBITDA(1) margin from 53% to approximately 47%.
(1) Adjusted operating EBITDA: This is a non-IFRS measure defined as operating income before interest, taxes, depreciation, amortization, stock based compensation, acquisition related expenses and asset impairment charges. Refer to the end of this document for the reconciliation of reported financial results to non-IFRS measures.
Edward Wright, Chief Executive Officer, commented, “If the new billing codes go into effect as currently proposed, we anticipate that our business will continue to generate strong adjusted operating EBITDA margins of approximately 47%. Our focus continues to be growing our business through acquisitions and organic growth, which will be funded from our cash flow from operations and existing credit facility.”
Antwort auf Beitrag Nr.: 55.342.199 von R-BgO am 17.07.17 21:13:00
CRH Increases Credit Facility to US$100 Million to Fund Additional Growth and Retire Crown Debt
JP Morgan Joins Syndicate of Lenders
VANCOUVER, B.C. – June 26, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”) announces that it has increased its credit facility (the “New Credit Facilities”) with a syndicate of lenders led by The Bank of Nova Scotia (“Scotiabank”).
The New Credit Facilities increase the amount of available credit from US$55 million to US$100 million and now consist of a US$75 million revolving credit facility and a US$25 million term facility. The syndicate, led by Scotiabank, includes US Bank National Association, Canada Branch (“U.S. Bank”) and has been expanded to include JP Morgan Chase Bank, N.A. (“JP Morgan”) as a new lender.
In addition, the New Credit Facilities provide CRH access to an uncommitted accordion facility that would increase the amount of revolving credit facilities available to CRH by US$25 million.
The New Credit Facilities will be used to fund future acquisitions by CRH and to repay all of the debt owing by CRH to Crown Capital Fund III Management Inc. (“Crown”) provided in December 2014 (the “Crown Debt”).
The New Credit Facilities also reduce the interest rate and the standby fees payable by CRH. The New Credit Facilities mature on June 26, 2020. The new term facility will be repaid in quarterly installments of 2.5% of the initial principal amount, with a balloon payment due upon maturity.
Richard Bear, Chief Financial Officer, stated, “We are pleased to announce our New Credit Facilities and the addition of JP Morgan to the lending syndicate. Our financial strength allows us to expand our access to low cost, non-dilutive capital to maintain our acquisition pace. We thank Scotiabank and U.S. Bank for their continued support and welcome JP Morgan as our newest partner”.
Features of the Amended Facilities include:
-Introduction of a US$25 million accordion feature
-Extension in maturity date to June 26, 2020
-Provides flexibility to CRH for additional acquisitions and a credit framework for future growth
-Lowers the cost of capital to approximately 3.50% per annum
-Allows CRH to repay the Crown Debt (which bears an interest rate of 12% per annum)
Edward Wright, Chief Operating Officer, added, “The New Credit Facilities will provide the funds required to finance acquisitions we expect to close this year, enable us to repay Crown, reduce our interest expense, and provide us a funding platform for future growth”. Mr. Wright continued, “Crown has been an excellent and supportive partner - without their support, our first acquisition back in December of 2014 would not have been possible.”
vorher gab's noch das:
...jedenfalls ist der Kurs inzwischen unter meinem Einstand von neulich;CRH Increases Credit Facility to US$100 Million to Fund Additional Growth and Retire Crown Debt
JP Morgan Joins Syndicate of Lenders
VANCOUVER, B.C. – June 26, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”) announces that it has increased its credit facility (the “New Credit Facilities”) with a syndicate of lenders led by The Bank of Nova Scotia (“Scotiabank”).
The New Credit Facilities increase the amount of available credit from US$55 million to US$100 million and now consist of a US$75 million revolving credit facility and a US$25 million term facility. The syndicate, led by Scotiabank, includes US Bank National Association, Canada Branch (“U.S. Bank”) and has been expanded to include JP Morgan Chase Bank, N.A. (“JP Morgan”) as a new lender.
In addition, the New Credit Facilities provide CRH access to an uncommitted accordion facility that would increase the amount of revolving credit facilities available to CRH by US$25 million.
The New Credit Facilities will be used to fund future acquisitions by CRH and to repay all of the debt owing by CRH to Crown Capital Fund III Management Inc. (“Crown”) provided in December 2014 (the “Crown Debt”).
The New Credit Facilities also reduce the interest rate and the standby fees payable by CRH. The New Credit Facilities mature on June 26, 2020. The new term facility will be repaid in quarterly installments of 2.5% of the initial principal amount, with a balloon payment due upon maturity.
Richard Bear, Chief Financial Officer, stated, “We are pleased to announce our New Credit Facilities and the addition of JP Morgan to the lending syndicate. Our financial strength allows us to expand our access to low cost, non-dilutive capital to maintain our acquisition pace. We thank Scotiabank and U.S. Bank for their continued support and welcome JP Morgan as our newest partner”.
Features of the Amended Facilities include:
-Introduction of a US$25 million accordion feature
-Extension in maturity date to June 26, 2020
-Provides flexibility to CRH for additional acquisitions and a credit framework for future growth
-Lowers the cost of capital to approximately 3.50% per annum
-Allows CRH to repay the Crown Debt (which bears an interest rate of 12% per annum)
Edward Wright, Chief Operating Officer, added, “The New Credit Facilities will provide the funds required to finance acquisitions we expect to close this year, enable us to repay Crown, reduce our interest expense, and provide us a funding platform for future growth”. Mr. Wright continued, “Crown has been an excellent and supportive partner - without their support, our first acquisition back in December of 2014 would not have been possible.”
CRH Medical Corporation Announces Majority Purchase of Anesthesia Practice in Central Colorado
VANCOUVER, B.C. – September 11, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”),announces that it has completed an accretive transaction whereby CRH has acquired a 51% interest in a gastroenterology (“GI”) anesthesia practice in Central Colorado (“Central Colorado”).
Central Colorado provides anesthesia services to three ambulatory surgical centers and is CRH’s second acquisition in Colorado. The transaction was financed through a combination of CRH’s credit facility and cash on hand.
Colorado transaction highlights:
* Total 2018 annual estimated revenue1 of US$5.6 million
* EBITDA and cash flow accretive
* Structured as joint venture with CRH retaining a 51% interest
1 Total 2018 annual estimated revenue takes into consideration the Centers for Medicare and Medicaid’s proposed 2018 Physician Fee Schedule. Please refer to our news release dated July 17, 2017 for more details.
Edward Wright, CEO of CRH, commented on the transaction, “We are excited to partner with another O’Regan customer to expand our presence in Colorado. This is further evidence of our ability to leverage our strong relationships to grow our anesthesia business.
As we have stated before, our acquisition pace during the remainder of the year is increasing and I look forward to updating you on our progress as we grow further.”
Mr. Wright added, “Our thoughts and prayers are with those in the path of Hurricane Irma. Our operations in Florida, especially those located in Cape Coral and Ft. Meyers will be impacted, the extent of which will be evaluated once the storm has passed.”
VANCOUVER, B.C. – September 11, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”),announces that it has completed an accretive transaction whereby CRH has acquired a 51% interest in a gastroenterology (“GI”) anesthesia practice in Central Colorado (“Central Colorado”).
Central Colorado provides anesthesia services to three ambulatory surgical centers and is CRH’s second acquisition in Colorado. The transaction was financed through a combination of CRH’s credit facility and cash on hand.
Colorado transaction highlights:
* Total 2018 annual estimated revenue1 of US$5.6 million
* EBITDA and cash flow accretive
* Structured as joint venture with CRH retaining a 51% interest
1 Total 2018 annual estimated revenue takes into consideration the Centers for Medicare and Medicaid’s proposed 2018 Physician Fee Schedule. Please refer to our news release dated July 17, 2017 for more details.
Edward Wright, CEO of CRH, commented on the transaction, “We are excited to partner with another O’Regan customer to expand our presence in Colorado. This is further evidence of our ability to leverage our strong relationships to grow our anesthesia business.
As we have stated before, our acquisition pace during the remainder of the year is increasing and I look forward to updating you on our progress as we grow further.”
Mr. Wright added, “Our thoughts and prayers are with those in the path of Hurricane Irma. Our operations in Florida, especially those located in Cape Coral and Ft. Meyers will be impacted, the extent of which will be evaluated once the storm has passed.”
Der Chart sieht ja richtig spannend und nach einer Konsolidierung aus. Welche konkreten Gründe gab es denn für die Viertelung?
Antwort auf Beitrag Nr.: 55.733.727 von Andrija am 13.09.17 16:09:00
2) weil es beim alten Preis mehr Verkäufer als Käufer gab und der Preis so weit runter musste, dass es ein neues Gleichgewicht gibt
Jeder, der behauptet, er "weiß" warum sich ein Preis bewegt, lügt und/oder ist nicht besonders schlau.
Habe natürlich ein paar Spekulationen, was Meinungswandel bei Investoren ausgelöst haben könnte:
-als gravierend sehe ich die in #8 thematisierte Medicaid-Vergütunsänderung
-dann sind die Zahlen zumindest optisch etwas am Schwächeln
-und man ist natürlich extrem geleveraged
Mich juckt's schon länger aufzustocken, aber der Preissturz macht schon vorsichtiger.
Meine Standardantworten:
1) weiß nicht2) weil es beim alten Preis mehr Verkäufer als Käufer gab und der Preis so weit runter musste, dass es ein neues Gleichgewicht gibt
Jeder, der behauptet, er "weiß" warum sich ein Preis bewegt, lügt und/oder ist nicht besonders schlau.
Habe natürlich ein paar Spekulationen, was Meinungswandel bei Investoren ausgelöst haben könnte:
-als gravierend sehe ich die in #8 thematisierte Medicaid-Vergütunsänderung
-dann sind die Zahlen zumindest optisch etwas am Schwächeln
-und man ist natürlich extrem geleveraged
Mich juckt's schon länger aufzustocken, aber der Preissturz macht schon vorsichtiger.
Antwort auf Beitrag Nr.: 55.723.896 von R-BgO am 12.09.17 16:00:23CRH Medical Corporation Announces Majority Purchase of an Anesthesia Practice in North Carolina and Provides an Outlook for Q3 2017
VANCOUVER, B.C. – September 22, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), announces that it has completed an accretive transaction whereby CRH has acquired a 51% interest in a gastroenterology (“GI”) anesthesia practice in Raleigh, North Carolina (“Raleigh”).
Raleigh provides anesthesia services to three ambulatory surgical centers in North Carolina. The transaction was financed through a combination of CRH’s credit facility and cash on hand.
Raleigh transaction highlights:
* Total 2018 annual estimated revenue1 of US$5.3 million
* EBITDA and cash flow accretive
* Structured as joint venture with CRH acquiring a 51% interest
1Total 2018 annual estimated revenue takes into consideration the Centers for Medicare and Medicaid’s proposed 2018 Physician Fee Schedule. Please refer to our news release dated July 17, 2017 for more details.
Outlook for Q3 2017
The Company is providing an outlook for the three months ending September 30, 2017. This outlook reflects:
(a) recent data implying that commercial insurance patient cases will not increase as much as expected in Q3 2017 compared to Q2 2017,
(b) the expected impact of Hurricane Irma on facilities we serve in the Southeastern United States resulting in approximately 1,500 procedures being cancelled, and
(c) the positive impact of our recently announced acquisitions.
The Company is providing this outlook to clarify shareholder expectations considering such factors affecting the Company. For the three months ending September 30, 2017, total revenue is expected to be approximately US$22.7 million. Adjusted Operating EBITDA2 attributable to shareholders for the period is estimated to be approximately US$7.3 million.
2Adjusted operating EBITDA is a non-IFRS measure defined as operating income before interest, taxes, depreciation and related expenses, amortization, stock-based compensation, acquisition-related expenses, and asset impairment charges. Refer to the Company’s Financial Report for the quarter ended June 30, 2017 for a reconciliation of reported financial results to non-IFRS measures.
Edward Wright, CEO of CRH, commented on the transaction, “We are thrilled to partner with Raleigh, another existing O’Regan customer, to grow our operations in North Carolina. This is our fifth acquisition this year and it brings us closer to achieving our anesthesia expansion objectives for 2017.”
VANCOUVER, B.C. – September 22, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), announces that it has completed an accretive transaction whereby CRH has acquired a 51% interest in a gastroenterology (“GI”) anesthesia practice in Raleigh, North Carolina (“Raleigh”).
Raleigh provides anesthesia services to three ambulatory surgical centers in North Carolina. The transaction was financed through a combination of CRH’s credit facility and cash on hand.
Raleigh transaction highlights:
* Total 2018 annual estimated revenue1 of US$5.3 million
* EBITDA and cash flow accretive
* Structured as joint venture with CRH acquiring a 51% interest
1Total 2018 annual estimated revenue takes into consideration the Centers for Medicare and Medicaid’s proposed 2018 Physician Fee Schedule. Please refer to our news release dated July 17, 2017 for more details.
Outlook for Q3 2017
The Company is providing an outlook for the three months ending September 30, 2017. This outlook reflects:
(a) recent data implying that commercial insurance patient cases will not increase as much as expected in Q3 2017 compared to Q2 2017,
(b) the expected impact of Hurricane Irma on facilities we serve in the Southeastern United States resulting in approximately 1,500 procedures being cancelled, and
(c) the positive impact of our recently announced acquisitions.
The Company is providing this outlook to clarify shareholder expectations considering such factors affecting the Company. For the three months ending September 30, 2017, total revenue is expected to be approximately US$22.7 million. Adjusted Operating EBITDA2 attributable to shareholders for the period is estimated to be approximately US$7.3 million.
2Adjusted operating EBITDA is a non-IFRS measure defined as operating income before interest, taxes, depreciation and related expenses, amortization, stock-based compensation, acquisition-related expenses, and asset impairment charges. Refer to the Company’s Financial Report for the quarter ended June 30, 2017 for a reconciliation of reported financial results to non-IFRS measures.
Edward Wright, CEO of CRH, commented on the transaction, “We are thrilled to partner with Raleigh, another existing O’Regan customer, to grow our operations in North Carolina. This is our fifth acquisition this year and it brings us closer to achieving our anesthesia expansion objectives for 2017.”
Antwort auf Beitrag Nr.: 55.805.061 von R-BgO am 22.09.17 20:21:05CRH Medical Corporation Announces the Purchase of Anesthesia Practice in San Antonio
VANCOUVER, B.C. – September 28, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), announces that it has completed an accretive transaction whereby CRH has acquired a gastroenterology (“GI”) anesthesia practice (100%) in San Antonio, Texas (“Alamo”).
Alamo provides anesthesia services to an ambulatory surgical center in San Antonio, TX and is CRH’s second acquisition in Texas. The transaction was financed through a combination of CRH’s credit facility and cash on hand.
Alamo transaction highlights:
* Total 2018 annual estimated revenue1 of US$1.8 million
* EBITDA and cash flow accretive
1Total 2018 annual estimated revenue takes into consideration the Centers for Medicare and Medicaid’s proposed 2018 Physician Fee Schedule. Please refer to our news release dated July 17, 2017 for more details.
Edward Wright, CEO of CRH, commented on the transaction, “We are very pleased to have completed our sixth anesthesia acquisition of 2017. Alamo, is an existing O’Regan customer and our second acquisition in Texas. We look forward to continue leveraging the strength of our O’Regan business to expand our anesthesia business further.”
VANCOUVER, B.C. – September 28, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), announces that it has completed an accretive transaction whereby CRH has acquired a gastroenterology (“GI”) anesthesia practice (100%) in San Antonio, Texas (“Alamo”).
Alamo provides anesthesia services to an ambulatory surgical center in San Antonio, TX and is CRH’s second acquisition in Texas. The transaction was financed through a combination of CRH’s credit facility and cash on hand.
Alamo transaction highlights:
* Total 2018 annual estimated revenue1 of US$1.8 million
* EBITDA and cash flow accretive
1Total 2018 annual estimated revenue takes into consideration the Centers for Medicare and Medicaid’s proposed 2018 Physician Fee Schedule. Please refer to our news release dated July 17, 2017 for more details.
Edward Wright, CEO of CRH, commented on the transaction, “We are very pleased to have completed our sixth anesthesia acquisition of 2017. Alamo, is an existing O’Regan customer and our second acquisition in Texas. We look forward to continue leveraging the strength of our O’Regan business to expand our anesthesia business further.”
Antwort auf Beitrag Nr.: 55.736.796 von R-BgO am 13.09.17 21:55:46Results of Operations – Three and Nine Months Ended September 30, 2017
Revenues for the quarter ended September 30, 2017 were $23,345,030 compared to $22,108,137 for the quarter ended September 30, 2016. The increase is mainly attributable to revenue contributions from the anesthesia businesses acquired by the Company in February and March of 2017, along with recent acquisitions in the third quarter of 2017. Revenues for the nine months ended September 30, 2017 were $67,939,226, an increase of $15,406,697 when compared to the nine months ended September 30, 2016.
Revenues from anesthesia services for the quarter ended September 30, 2017 were $20,480,288 compared to $19,446,645 for the third quarter of 2016. The increase was primarily due to the Company’s anesthesia acquisitions throughout 2017; however, there were a number of factors which impacted the change between the third quarter of 2017 and the third quarter of 2016.
The increase in revenue from the prior period is reflective of the following:
-growth through acquisitions contributed $2.7 million of the increase when comparing the two periods;
-despite growth in the number of cases serviced compared to 2016, a change in our payor mix and rates within our commercial payors contributed a decrease in revenue of $1.8 million when compared to revenues from 2016. Again, this is largely isolated within our GAA location. Excluding the impact of this change in payor mix in GAA, organic volume growth would have contributed approximately $0.1 million;
-a positive adjustment as a result of changes in revenue estimates relating to prior periods of $0.1 million, when compared to the third quarter of 2016; and,
-revenue growth from our exclusive agreement to develop and manage a monitored anesthesia care program with Puget Sound Gastroenterology of approximately $0.2 million (see recent events).
Anesthesia revenues for the nine months ended September 30, 2017 were $59,510,491 compared to $44,813,732 for the nine months ended September 30, 2016. The increase in revenue from the prior period is reflective of the following:
-increased revenue from acquisitions, both those completed mid-2016 and in 2017, of $18.1 million;
-despite growth in the number of cases serviced compared to 2016, a change in our payor mix and rates within our commercial payors contributed a decrease in revenue of $3.9 million when compared to revenues from 2016. Again, this is largely isolated within our GAA location. Excluding the impact of this change in payor mix in GAA, organic volume growth would have contributed approximately $1.5 million;
a positive adjustment as a result of changes in revenue estimates relating to prior periods of $0.1 million, when compared to the 2016 year to date period; and
-revenue growth from our exclusive agreement with Puget Sound Gastroenterology of approximately $0.4 million (see recent events).
During the three and nine months ended September 30, 2017, there were the following factors that impacted revenue which also impacted operating income and adjusted operating EBITDA when compared to both the previous year and previous quarter:
Revenue is affected by changes in the percentage of patient cases covered by commercial insurance versus federal insurance and commercial payor mix changes that result from the annual process that insured individuals and companies go through when renewing their health insurance policies. Changes in payor mix could have a positive or negative impact on revenues. The commercial payor mix changes described above primarily relate to one payor at GAA. Any future payor mix changes related to this payor are expected to not be material; and
Estimates are required in the determination of anesthesia services revenue. Each quarter we review our estimated revenue assumptions and make changes in estimates as required based on actual revenue collected. In the third quarter of 2017, we had a small negative adjustment of $100,000 related to changes in revenue estimates; this relatively small adjustment is reflective of the Company’s stable platform of entities and our growing experience in estimating revenue rates per unit.
In the nine months ended September 30, 2017, we experienced a positive revenue adjustment in relation to our revenue estimates of approximately $0.8 million. This largely results from estimates adjusted in the first quarter of this year. Adjustments to our anesthesia revenues impact not only revenue, but also operating income and adjusted operating EBITDA.
In the quarter ended September 30, 2017, the anesthesia services segment serviced 49,113 patient cases compared to 42,203 patient cases during the quarter ended September 30, 2016. Year to date patient cases total 137,664 compared to 95,979 cases in the nine months ended September 30, 2016.
Revenues from product sales for the quarter ended September 30, 2017 were $2,864,742 compared to $2,661,492 for the third quarter of 2016. The increase in product sales is the result of the continuing successful execution of the Company’s direct to physician program that allows physicians to purchase our hemorrhoid banding technology, treatment protocols, marketing and operational experience.
Revenues from product sales for the nine months ended September 30, 2017 were $8,428,735 compared to $7,718,797 for the nine months ended September 30, 2016. As of September 30, 2017, the Company has trained 2,620 physicians to use the O’Regan System, representing 1,011 clinical practices. This compares to 2,355 physicians trained, representing 902 clinical practices, as of September 30, 2016.
For the three months ended September 30, 2017, total adjusted operating expenses were $12,450,936 compared to $10,452,800 for the quarter ended September 30, 2016. For the nine months ended September 30, 2017, total adjusted operating expenses were $35,767,285 compared to $25,542,794 for the nine months ended September 30, 2016. Increases in adjusted operating expenses are primarily related to adjusted operating expenses in the anesthesia services business. Factors impacting the fluctuation of total adjusted operating expenses are consistent with those impacting operating expenses.
Anesthesia services adjusted operating expenses for the quarter ended September 30, 2017 were $10,362,959, compared to $8,794,079 for the three months ended September 30, 2016. Anesthesia services adjusted operating expenses primarily include labor related costs for Certified Registered Nurse Anesthetists and MD anesthesiologists, medical drugs and supplies, and billing and management related expenses. The Company’s first anesthesia acquisition was in the fourth quarter of 2014, with fourteen further acquisitions completed in 2015, 2016 and in the nine months ended September 30, 2017. As a result, the third quarter of 2017 is not directly comparable to 2016, with the majority of the increase relating to operating expenses for acquired companies and as a result of infrastructure investments made by the Company throughout 2017. As the Company works toward its acquisition strategy, it has invested in resources and infrastructure to support its initiatives. The investment in resource and infrastructure contributed approximately $300,000 in anesthesia adjusted operating expenses in the quarter. Though quarterly revenue may fluctuate significantly, quarterly adjusted operating expenses which are primarily employee related costs, due to their fixed nature, are not expected to fluctuate materially. These expenses are primarily impacted by the Company’s acquisition strategy. Anesthesia services adjusted operating expenses for the nine months ended September 30, 2017 were $29,671,929 compared to $20,275,129 for the nine months ended September 30, 2016. Similar to the third quarter of 2017, the first nine months of 2017 is not comparable to the first nine months of 2016 due to the timing of acquisitions. Investments in infrastructure and resources contributed approximately $1.1 million to anesthesia services adjusted operating expenses in the year to date period.
Product sales adjusted operating expenses for the quarter ended September 30, 2017 were $1,094,305 compared to $974,257 for the quarter ended September 30, 2016. The increase in product sales adjusted operating expenses compared to 2016 is a reflection of higher employee related costs as a result of increased sales activity as well as an increase in professional fees related to continuing efforts to distribute our product in China. Product sales expenses primarily include employee wages, product cost and support, marketing programs, office expenses, professional fees, and insurance. In the future, the Company expects adjusted operating expenses to increase as the Company continues to invest in activities aimed at increasing demand for training and use of the CRH O’Regan System. Product sales adjusted operating expenses for the nine months ended September 30, 2017 were $3,273,259 compared to $2,976,377 for the nine months ended September 30, 2016.
Corporate adjusted operating expenses for the quarter ended September 30, 2017 were $993,672 compared to $684,464 for the quarter ended September 30, 2016. The increase in corporate adjusted operating expense is a reflection of higher professional fees and employee related costs, and, in general, is reflective of the increasing complexity of our business which is also increasing our compliance costs. Corporate adjusted operating expenses for the nine months ended September 30, 2017 were $2,822,097 compared to $2,291,288 for the nine months ended September 30, 2016.
Adjusted operating EBITDA attributable to shareholders of the Company for the quarter ended September 30, 2017 was $7,775,349, a decrease of $1,346,933 from the quarter ended September 30, 2016. The decrease in adjusted operating EBITDA attributable to shareholders is primarily a reflection of the negative revenue rate and payor mix variances recorded in the quarter in respect of the Company’s anesthesia providers acquired prior to 2016. Adjusted operating EBITDA attributable to shareholders of the Company for the nine months ended September 30, 2017 was $22,846,790, an increase of $757,054 from the same period in 2016.
Total adjusted operating EBITDA was $10,894,094 for the quarter ended September 30, 2017, a decrease of $761,243 from the same period in 2016. Total adjusted operating EBITDA was $32,171,941 for the nine months ended September 30, 2017, an increase of $5,182,206 from the same period in 2016.
At September 30, 2017, the Company had $10,361,977 in cash and cash equivalents compared to $9,507,004 at the end of 2016. The increase in cash and equivalents is primarily a reflection of cash generated from operations and debt financing activities, less cash used to finance acquisitions during the first nine months of 2017, less repayment of debt in the period.
Working capital was $13,083,449 compared to working capital of $9,657,303 at December 31, 2016. The Company expects to meet its short-term obligations, including short-term obligations in respect of its notes payable and deferred consideration through cash earned through operating activities. The average number of days receivables outstanding at September 30, 2017 was 39 days. At December 31, 2016, the average number of days receivables outstanding was 34 days.
Revenues for the quarter ended September 30, 2017 were $23,345,030 compared to $22,108,137 for the quarter ended September 30, 2016. The increase is mainly attributable to revenue contributions from the anesthesia businesses acquired by the Company in February and March of 2017, along with recent acquisitions in the third quarter of 2017. Revenues for the nine months ended September 30, 2017 were $67,939,226, an increase of $15,406,697 when compared to the nine months ended September 30, 2016.
Revenues from anesthesia services for the quarter ended September 30, 2017 were $20,480,288 compared to $19,446,645 for the third quarter of 2016. The increase was primarily due to the Company’s anesthesia acquisitions throughout 2017; however, there were a number of factors which impacted the change between the third quarter of 2017 and the third quarter of 2016.
The increase in revenue from the prior period is reflective of the following:
-growth through acquisitions contributed $2.7 million of the increase when comparing the two periods;
-despite growth in the number of cases serviced compared to 2016, a change in our payor mix and rates within our commercial payors contributed a decrease in revenue of $1.8 million when compared to revenues from 2016. Again, this is largely isolated within our GAA location. Excluding the impact of this change in payor mix in GAA, organic volume growth would have contributed approximately $0.1 million;
-a positive adjustment as a result of changes in revenue estimates relating to prior periods of $0.1 million, when compared to the third quarter of 2016; and,
-revenue growth from our exclusive agreement to develop and manage a monitored anesthesia care program with Puget Sound Gastroenterology of approximately $0.2 million (see recent events).
Anesthesia revenues for the nine months ended September 30, 2017 were $59,510,491 compared to $44,813,732 for the nine months ended September 30, 2016. The increase in revenue from the prior period is reflective of the following:
-increased revenue from acquisitions, both those completed mid-2016 and in 2017, of $18.1 million;
-despite growth in the number of cases serviced compared to 2016, a change in our payor mix and rates within our commercial payors contributed a decrease in revenue of $3.9 million when compared to revenues from 2016. Again, this is largely isolated within our GAA location. Excluding the impact of this change in payor mix in GAA, organic volume growth would have contributed approximately $1.5 million;
a positive adjustment as a result of changes in revenue estimates relating to prior periods of $0.1 million, when compared to the 2016 year to date period; and
-revenue growth from our exclusive agreement with Puget Sound Gastroenterology of approximately $0.4 million (see recent events).
During the three and nine months ended September 30, 2017, there were the following factors that impacted revenue which also impacted operating income and adjusted operating EBITDA when compared to both the previous year and previous quarter:
Revenue is affected by changes in the percentage of patient cases covered by commercial insurance versus federal insurance and commercial payor mix changes that result from the annual process that insured individuals and companies go through when renewing their health insurance policies. Changes in payor mix could have a positive or negative impact on revenues. The commercial payor mix changes described above primarily relate to one payor at GAA. Any future payor mix changes related to this payor are expected to not be material; and
Estimates are required in the determination of anesthesia services revenue. Each quarter we review our estimated revenue assumptions and make changes in estimates as required based on actual revenue collected. In the third quarter of 2017, we had a small negative adjustment of $100,000 related to changes in revenue estimates; this relatively small adjustment is reflective of the Company’s stable platform of entities and our growing experience in estimating revenue rates per unit.
In the nine months ended September 30, 2017, we experienced a positive revenue adjustment in relation to our revenue estimates of approximately $0.8 million. This largely results from estimates adjusted in the first quarter of this year. Adjustments to our anesthesia revenues impact not only revenue, but also operating income and adjusted operating EBITDA.
In the quarter ended September 30, 2017, the anesthesia services segment serviced 49,113 patient cases compared to 42,203 patient cases during the quarter ended September 30, 2016. Year to date patient cases total 137,664 compared to 95,979 cases in the nine months ended September 30, 2016.
Revenues from product sales for the quarter ended September 30, 2017 were $2,864,742 compared to $2,661,492 for the third quarter of 2016. The increase in product sales is the result of the continuing successful execution of the Company’s direct to physician program that allows physicians to purchase our hemorrhoid banding technology, treatment protocols, marketing and operational experience.
Revenues from product sales for the nine months ended September 30, 2017 were $8,428,735 compared to $7,718,797 for the nine months ended September 30, 2016. As of September 30, 2017, the Company has trained 2,620 physicians to use the O’Regan System, representing 1,011 clinical practices. This compares to 2,355 physicians trained, representing 902 clinical practices, as of September 30, 2016.
For the three months ended September 30, 2017, total adjusted operating expenses were $12,450,936 compared to $10,452,800 for the quarter ended September 30, 2016. For the nine months ended September 30, 2017, total adjusted operating expenses were $35,767,285 compared to $25,542,794 for the nine months ended September 30, 2016. Increases in adjusted operating expenses are primarily related to adjusted operating expenses in the anesthesia services business. Factors impacting the fluctuation of total adjusted operating expenses are consistent with those impacting operating expenses.
Anesthesia services adjusted operating expenses for the quarter ended September 30, 2017 were $10,362,959, compared to $8,794,079 for the three months ended September 30, 2016. Anesthesia services adjusted operating expenses primarily include labor related costs for Certified Registered Nurse Anesthetists and MD anesthesiologists, medical drugs and supplies, and billing and management related expenses. The Company’s first anesthesia acquisition was in the fourth quarter of 2014, with fourteen further acquisitions completed in 2015, 2016 and in the nine months ended September 30, 2017. As a result, the third quarter of 2017 is not directly comparable to 2016, with the majority of the increase relating to operating expenses for acquired companies and as a result of infrastructure investments made by the Company throughout 2017. As the Company works toward its acquisition strategy, it has invested in resources and infrastructure to support its initiatives. The investment in resource and infrastructure contributed approximately $300,000 in anesthesia adjusted operating expenses in the quarter. Though quarterly revenue may fluctuate significantly, quarterly adjusted operating expenses which are primarily employee related costs, due to their fixed nature, are not expected to fluctuate materially. These expenses are primarily impacted by the Company’s acquisition strategy. Anesthesia services adjusted operating expenses for the nine months ended September 30, 2017 were $29,671,929 compared to $20,275,129 for the nine months ended September 30, 2016. Similar to the third quarter of 2017, the first nine months of 2017 is not comparable to the first nine months of 2016 due to the timing of acquisitions. Investments in infrastructure and resources contributed approximately $1.1 million to anesthesia services adjusted operating expenses in the year to date period.
Product sales adjusted operating expenses for the quarter ended September 30, 2017 were $1,094,305 compared to $974,257 for the quarter ended September 30, 2016. The increase in product sales adjusted operating expenses compared to 2016 is a reflection of higher employee related costs as a result of increased sales activity as well as an increase in professional fees related to continuing efforts to distribute our product in China. Product sales expenses primarily include employee wages, product cost and support, marketing programs, office expenses, professional fees, and insurance. In the future, the Company expects adjusted operating expenses to increase as the Company continues to invest in activities aimed at increasing demand for training and use of the CRH O’Regan System. Product sales adjusted operating expenses for the nine months ended September 30, 2017 were $3,273,259 compared to $2,976,377 for the nine months ended September 30, 2016.
Corporate adjusted operating expenses for the quarter ended September 30, 2017 were $993,672 compared to $684,464 for the quarter ended September 30, 2016. The increase in corporate adjusted operating expense is a reflection of higher professional fees and employee related costs, and, in general, is reflective of the increasing complexity of our business which is also increasing our compliance costs. Corporate adjusted operating expenses for the nine months ended September 30, 2017 were $2,822,097 compared to $2,291,288 for the nine months ended September 30, 2016.
Adjusted operating EBITDA attributable to shareholders of the Company for the quarter ended September 30, 2017 was $7,775,349, a decrease of $1,346,933 from the quarter ended September 30, 2016. The decrease in adjusted operating EBITDA attributable to shareholders is primarily a reflection of the negative revenue rate and payor mix variances recorded in the quarter in respect of the Company’s anesthesia providers acquired prior to 2016. Adjusted operating EBITDA attributable to shareholders of the Company for the nine months ended September 30, 2017 was $22,846,790, an increase of $757,054 from the same period in 2016.
Total adjusted operating EBITDA was $10,894,094 for the quarter ended September 30, 2017, a decrease of $761,243 from the same period in 2016. Total adjusted operating EBITDA was $32,171,941 for the nine months ended September 30, 2017, an increase of $5,182,206 from the same period in 2016.
At September 30, 2017, the Company had $10,361,977 in cash and cash equivalents compared to $9,507,004 at the end of 2016. The increase in cash and equivalents is primarily a reflection of cash generated from operations and debt financing activities, less cash used to finance acquisitions during the first nine months of 2017, less repayment of debt in the period.
Working capital was $13,083,449 compared to working capital of $9,657,303 at December 31, 2016. The Company expects to meet its short-term obligations, including short-term obligations in respect of its notes payable and deferred consideration through cash earned through operating activities. The average number of days receivables outstanding at September 30, 2017 was 39 days. At December 31, 2016, the average number of days receivables outstanding was 34 days.
CRH Medical Comments on the Centers for Medicare and Medicaid Services Final 2018 Physician Fee Schedule
VANCOUVER, B.C. – November 3, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), commented on the Centers for Medicare and Medicaid Services (“CMS”) final physician fee schedule (the “Final Rule”) for 2018, which was announced on November 2, 2017 and updates payment policies, payment rates, and other provisions for services furnished under the Medicare Physician Fee Schedule effective on January 1, 2018.
As proposed by CMS on July 13, 2017, the Final Rule confirms the introduction of CPT codes 00731 and 00732 for anesthesia furnished during upper endoscopic procedures and codes 00811, 00812, and 00813 for anesthesia furnished during lower endoscopic procedures.
The Final Rule, which goes into effect on January 1, 2018, confirms the proposal to set the number of base units for code 00731 at 5, the base units for code 00732 at 6, the base units for code 00811 at 4, and the base units for code 00813 at 5. However, the Final Rule further reduces the number of base units for code 00812 from the proposed 4 base units to 3 base units.
The Company expects the new codes and base unit values will be adopted by all commercial and federal payors effective January 1, 2018.
On July 17, 2017, the Company announced that the estimated impact from the proposed changes would be that anesthesia revenues would decrease by approximately 8.5% and total revenue would decrease by approximately 7.5%. The Company also estimated that our total adjusted operating EBITDA (1) would decrease by approximately 13.5%.
We estimate that the impact from the Final Rule, if applied to our most recent financial results, would result in a decrease of approximately 12% of anesthesia revenue and a decrease of approximately 10.5% of total Company revenue. Total adjusted operating EBITDA (1) will decrease approximately 20%.
Edward Wright, Chief Executive Officer, commented, “As a result of the CMS announcement of the Final Rule, we now have clarity on the impact to our business. Even with these changes, we expect our business would generate healthy operating EBITDA margins of approximately 43%, and we look forward to growing our business with more certainty.”
VANCOUVER, B.C. – November 3, 2017 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), commented on the Centers for Medicare and Medicaid Services (“CMS”) final physician fee schedule (the “Final Rule”) for 2018, which was announced on November 2, 2017 and updates payment policies, payment rates, and other provisions for services furnished under the Medicare Physician Fee Schedule effective on January 1, 2018.
As proposed by CMS on July 13, 2017, the Final Rule confirms the introduction of CPT codes 00731 and 00732 for anesthesia furnished during upper endoscopic procedures and codes 00811, 00812, and 00813 for anesthesia furnished during lower endoscopic procedures.
The Final Rule, which goes into effect on January 1, 2018, confirms the proposal to set the number of base units for code 00731 at 5, the base units for code 00732 at 6, the base units for code 00811 at 4, and the base units for code 00813 at 5. However, the Final Rule further reduces the number of base units for code 00812 from the proposed 4 base units to 3 base units.
The Company expects the new codes and base unit values will be adopted by all commercial and federal payors effective January 1, 2018.
On July 17, 2017, the Company announced that the estimated impact from the proposed changes would be that anesthesia revenues would decrease by approximately 8.5% and total revenue would decrease by approximately 7.5%. The Company also estimated that our total adjusted operating EBITDA (1) would decrease by approximately 13.5%.
We estimate that the impact from the Final Rule, if applied to our most recent financial results, would result in a decrease of approximately 12% of anesthesia revenue and a decrease of approximately 10.5% of total Company revenue. Total adjusted operating EBITDA (1) will decrease approximately 20%.
Edward Wright, Chief Executive Officer, commented, “As a result of the CMS announcement of the Final Rule, we now have clarity on the impact to our business. Even with these changes, we expect our business would generate healthy operating EBITDA margins of approximately 43%, and we look forward to growing our business with more certainty.”
CRH Medical Receives TSX Approval for Normal Course Issuer Bid
VANCOUVER, B.C. – November 7, 2017 –
CRH Medical Corporation- CRH Medical Corporation (the “Company”) (TSX: CRH) (NYSE American: CRHM), announces that it has received approval from the Toronto Stock Exchange (“TSX”) of its Notice of Intention to Make a Normal Course Issuer Bid (the “Bid”).
Pursuant to the Bid, the Company may purchase for cancellation up to 7,120,185 of its common shares (“Common Shares”), or approximately 10% of the Common Shares outstanding as of the date of this announcement (representing 10% of the public float). As of October 31, 2017, there were 74,127,238 Common Shares of the Company issued and outstanding, and the public float consisted of 71,201,855 Common Shares.
The Bid is being adopted in addition to, and not as a substitute for, other investments in growth opportunities historically undertaken and contemplated by the Company. The Bid will be funded through the Company’s internally generated cash flow from operations.
The purchases will be made by the Company through the facilities and in accordance with the rules of the TSX and Rule 10b-18 (“Rule 10b-18”) under the U.S. Securities Exchange Act of 1934, as amended (“the “Exchange Act”), and the price which the Company will pay for any such Common Shares will be the market price at the time of acquisition. The Company will make no purchases of Common Shares other than open market purchases or other means approved by the TSX. Other than block purchases allowable under the TSX rules, purchases will be subject to a daily restriction of 103,902 Common Shares, being 25% of the average daily trading volume for the preceding six months.
In addition, purchases of Common Shares through the facilities of the NYSE American stock exchange (“NYSE American”) will be made in compliance with Rule 10b-18, which contains similar restrictions on the number of shares that may be repurchased based on the average daily trading volumes of the Common Shares on NYSE American, subject to certain exceptions for block purchases. In addition, purchases may also be made through other Canadian and U.S. marketplaces.
The actual number of Common Shares of the Company that are purchased for cancellation under the Bid, if any, and the timing of such purchases will be determined by the Company. The Board of Directors of the Company believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds.
The Company intends to establish an automatic purchase plan (the “Plan”) under which its broker may purchase Common Shares according to a prearranged set of criteria. The plan will enable the purchase of Common Shares at any time, including when the Company would not ordinarily be active in the market because of internal trading blackout periods, insider trading rules or otherwise. The purchases under the automatic purchase plan will be made in accordance with Rule 10b5-1 under the Exchange Act (“Rule 10b5-1”). The Plan will terminate on the earliest of: the date on which the purchase limits specified in the Plan have been attained, the date on which the Bid terminates or the date on which the Plan is terminated by a party in accordance with its terms. To the knowledge of the Company, no director, senior officer or other insider of the Company currently intends to sell any Common Shares under this Bid. However, sales by such persons through the facilities of the TSX or NYSE American may occur if the personal circumstances of any such person changes or any such person makes a decision unrelated to these normal course purchases. The benefits to any such person whose shares are purchased would be the same as the benefits available to all other holders whose shares are purchased.
The Bid will commence on November 9, 2017 with first purchases under the Plan beginning November 20, 2017 and will terminate on the earlier of: (i) November 8, 2018, (ii) the date the Company completes its purchases pursuant to the notice of intention filed with the TSX, or (iii) the date of notice by the Company of termination of the Bid. The Company has not made any purchases of Common Shares pursuant to a normal course issuer bid within the previous 12 months.
VANCOUVER, B.C. – November 7, 2017 –
CRH Medical Corporation- CRH Medical Corporation (the “Company”) (TSX: CRH) (NYSE American: CRHM), announces that it has received approval from the Toronto Stock Exchange (“TSX”) of its Notice of Intention to Make a Normal Course Issuer Bid (the “Bid”).
Pursuant to the Bid, the Company may purchase for cancellation up to 7,120,185 of its common shares (“Common Shares”), or approximately 10% of the Common Shares outstanding as of the date of this announcement (representing 10% of the public float). As of October 31, 2017, there were 74,127,238 Common Shares of the Company issued and outstanding, and the public float consisted of 71,201,855 Common Shares.
The Bid is being adopted in addition to, and not as a substitute for, other investments in growth opportunities historically undertaken and contemplated by the Company. The Bid will be funded through the Company’s internally generated cash flow from operations.
The purchases will be made by the Company through the facilities and in accordance with the rules of the TSX and Rule 10b-18 (“Rule 10b-18”) under the U.S. Securities Exchange Act of 1934, as amended (“the “Exchange Act”), and the price which the Company will pay for any such Common Shares will be the market price at the time of acquisition. The Company will make no purchases of Common Shares other than open market purchases or other means approved by the TSX. Other than block purchases allowable under the TSX rules, purchases will be subject to a daily restriction of 103,902 Common Shares, being 25% of the average daily trading volume for the preceding six months.
In addition, purchases of Common Shares through the facilities of the NYSE American stock exchange (“NYSE American”) will be made in compliance with Rule 10b-18, which contains similar restrictions on the number of shares that may be repurchased based on the average daily trading volumes of the Common Shares on NYSE American, subject to certain exceptions for block purchases. In addition, purchases may also be made through other Canadian and U.S. marketplaces.
The actual number of Common Shares of the Company that are purchased for cancellation under the Bid, if any, and the timing of such purchases will be determined by the Company. The Board of Directors of the Company believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds.
The Company intends to establish an automatic purchase plan (the “Plan”) under which its broker may purchase Common Shares according to a prearranged set of criteria. The plan will enable the purchase of Common Shares at any time, including when the Company would not ordinarily be active in the market because of internal trading blackout periods, insider trading rules or otherwise. The purchases under the automatic purchase plan will be made in accordance with Rule 10b5-1 under the Exchange Act (“Rule 10b5-1”). The Plan will terminate on the earliest of: the date on which the purchase limits specified in the Plan have been attained, the date on which the Bid terminates or the date on which the Plan is terminated by a party in accordance with its terms. To the knowledge of the Company, no director, senior officer or other insider of the Company currently intends to sell any Common Shares under this Bid. However, sales by such persons through the facilities of the TSX or NYSE American may occur if the personal circumstances of any such person changes or any such person makes a decision unrelated to these normal course purchases. The benefits to any such person whose shares are purchased would be the same as the benefits available to all other holders whose shares are purchased.
The Bid will commence on November 9, 2017 with first purchases under the Plan beginning November 20, 2017 and will terminate on the earlier of: (i) November 8, 2018, (ii) the date the Company completes its purchases pursuant to the notice of intention filed with the TSX, or (iii) the date of notice by the Company of termination of the Bid. The Company has not made any purchases of Common Shares pursuant to a normal course issuer bid within the previous 12 months.
nochmal nachgelegt
höchst volatil die Butze,
und es sieht nach einem weiteren down-Jahr aus...
Antwort auf Beitrag Nr.: 56.130.314 von R-BgO am 08.11.17 12:12:44CRH Medical Receives TSX Approval for Renewal of Normal Course Issuer Bid
VANCOUVER, November 5, 2018 -
CRH Medical Corporation (the “Company”) (TSX: CRH) (NYSE American: CRHM), announces that it has received approval from the Toronto Stock Exchange (“TSX”) of its Notice of Intention to renew its existing Normal Course Issuer Bid (the “Bid”).
Pursuant to the Bid, the Company may purchase for cancellation up to 7,044,410 of its common shares (“Common Shares”), or approximately 9.74% of the Common Shares outstanding as of the date of this announcement (representing 10% of the public float). As of October 31, 2018, there were 72,323,738 Common Shares of the Company issued and outstanding, and the public float consisted of 70,444,105 Common Shares.
The Bid is being adopted in addition to, and not as a substitute for, other investments in growth opportunities historically undertaken and contemplated by the Company. The Bid will be funded through the Company’s internally generated cash flow from operations.
The purchases will be made by the Company through the facilities and in accordance with the rules of the TSX and Rule 10b-18 (“Rule 10b-18”) under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the price which the Company will pay for any such Common Shares will be the market price at the time of acquisition. The Company will make no purchases of Common Shares other than open market purchases or other means approved by the TSX. Other than block purchases allowable under the TSX rules, purchases will be subject to a daily restriction of 46,958 Common Shares, being 25% of the average daily trading volume for the preceding six months. In addition, purchases of Common Shares through the facilities of the NYSE American stock exchange (“NYSE American”) will be made in compliance with Rule 10b-18, which contains similar restrictions on the number of shares that may be repurchased based on the average daily trading volumes of the Common Shares on NYSE American, subject to certain exceptions for block purchases.
The actual number of Common Shares of the Company that are purchased for cancellation under the Bid, if any, and the timing of such purchases will be determined by the Company. The Board of Directors of the Company believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds.
The Company expects to renew its automatic purchase plan (the “Plan”) under which its broker may purchase Common Shares according to a prearranged set of criteria. The Plan will enable the purchase of Common Shares at any time, including when the Company would not ordinarily be active in the market because of internal trading blackout periods, insider trading rules or otherwise. The purchases under the Plan will be made in accordance with Rule 10b5-1 under the Exchange Act (“Rule 10b5-1”). The Plan will terminate on the earliest of: the date on which the purchase limits specified in the Plan have been attained, the date on which the Bid terminates or the date on which the Plan is terminated by a party in accordance with its terms. To the knowledge of the Company, no director, senior officer or other insider of the Company currently intends to sell any Common Shares under the Bid. However, sales by such persons through the facilities of the TSX or NYSE American may occur if the personal circumstances of any such person changes or any such person makes a decision unrelated to these purchases under the Bid. The benefits to any such person whose shares are purchased would be the same as the benefits available to all other holders whose shares are purchased.
The Bid will commence on November 9, 2018, with first purchases under the Plan beginning November 19, 2018, and will terminate on the earlier of: (i) November 8, 2019, (ii) the date the Company completes its purchases pursuant to the notice of intention filed with the TSX, or (iii) the date of notice by the Company of termination of the Bid.
For its current normal course issuer bid that expires on November 8, 2018, the Company previously sought and received approval from the TSX to purchase up to a maximum of 7,120,185 Common Shares. Through facilities of the TSX and the NYSE American, the Company re-purchased and cancelled 2,238,700 of its Common Shares for a total cost of CAD $7,005,369.60. The volume weighted average purchase price paid for the shares was approximately CAD $3.13.
VANCOUVER, November 5, 2018 -
CRH Medical Corporation (the “Company”) (TSX: CRH) (NYSE American: CRHM), announces that it has received approval from the Toronto Stock Exchange (“TSX”) of its Notice of Intention to renew its existing Normal Course Issuer Bid (the “Bid”).
Pursuant to the Bid, the Company may purchase for cancellation up to 7,044,410 of its common shares (“Common Shares”), or approximately 9.74% of the Common Shares outstanding as of the date of this announcement (representing 10% of the public float). As of October 31, 2018, there were 72,323,738 Common Shares of the Company issued and outstanding, and the public float consisted of 70,444,105 Common Shares.
The Bid is being adopted in addition to, and not as a substitute for, other investments in growth opportunities historically undertaken and contemplated by the Company. The Bid will be funded through the Company’s internally generated cash flow from operations.
The purchases will be made by the Company through the facilities and in accordance with the rules of the TSX and Rule 10b-18 (“Rule 10b-18”) under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the price which the Company will pay for any such Common Shares will be the market price at the time of acquisition. The Company will make no purchases of Common Shares other than open market purchases or other means approved by the TSX. Other than block purchases allowable under the TSX rules, purchases will be subject to a daily restriction of 46,958 Common Shares, being 25% of the average daily trading volume for the preceding six months. In addition, purchases of Common Shares through the facilities of the NYSE American stock exchange (“NYSE American”) will be made in compliance with Rule 10b-18, which contains similar restrictions on the number of shares that may be repurchased based on the average daily trading volumes of the Common Shares on NYSE American, subject to certain exceptions for block purchases.
The actual number of Common Shares of the Company that are purchased for cancellation under the Bid, if any, and the timing of such purchases will be determined by the Company. The Board of Directors of the Company believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds.
The Company expects to renew its automatic purchase plan (the “Plan”) under which its broker may purchase Common Shares according to a prearranged set of criteria. The Plan will enable the purchase of Common Shares at any time, including when the Company would not ordinarily be active in the market because of internal trading blackout periods, insider trading rules or otherwise. The purchases under the Plan will be made in accordance with Rule 10b5-1 under the Exchange Act (“Rule 10b5-1”). The Plan will terminate on the earliest of: the date on which the purchase limits specified in the Plan have been attained, the date on which the Bid terminates or the date on which the Plan is terminated by a party in accordance with its terms. To the knowledge of the Company, no director, senior officer or other insider of the Company currently intends to sell any Common Shares under the Bid. However, sales by such persons through the facilities of the TSX or NYSE American may occur if the personal circumstances of any such person changes or any such person makes a decision unrelated to these purchases under the Bid. The benefits to any such person whose shares are purchased would be the same as the benefits available to all other holders whose shares are purchased.
The Bid will commence on November 9, 2018, with first purchases under the Plan beginning November 19, 2018, and will terminate on the earlier of: (i) November 8, 2019, (ii) the date the Company completes its purchases pursuant to the notice of intention filed with the TSX, or (iii) the date of notice by the Company of termination of the Bid.
For its current normal course issuer bid that expires on November 8, 2018, the Company previously sought and received approval from the TSX to purchase up to a maximum of 7,120,185 Common Shares. Through facilities of the TSX and the NYSE American, the Company re-purchased and cancelled 2,238,700 of its Common Shares for a total cost of CAD $7,005,369.60. The volume weighted average purchase price paid for the shares was approximately CAD $3.13.
wenn man wüßte, wie groß der tatsächliche ökonomische Wertverlust vs. Abschreibungen ist...
CRH Medical Corporation Appoints Seasoned Healthcare Executive, Dr. Tushar Ramani, as new CEO
VANCOUVER, B.C. – April 9, 2019 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”), today announced the appointment of Dr. Tushar Ramani as CEO of the Company, replacing outgoing CEO Edward Wright. Dr. Ramani, a 30 year veteran of the anesthesia industry, will also join the Company’s board as a director, in place of Mr. Wright.
“We would like first to thank Edward Wright for his long service and for leading the transformation of the Company into the gastrointestinal anesthesia business” commented Dr. Anthony Holler, Chairman of the Board of the Company. “While we have enjoyed tremendous growth, the Board of Directors believes it is time to take the next step in our development and we believe Tushar is the perfect executive to lead us. Tushar brings extensive experience in both managing and providing healthcare services, growing companies and creating shareholder value.”
Dr. Ramani was a co-founder and president of Anesthetix Management, LLC, a national provider of comprehensive anesthesiology and pain management solutions to hospitals and surgery centers, which was acquired by TeamHealth Holdings, Inc., a physician services organization listed on the NYSE at that time. Dr. Ramani remained as President of TeamHealth's Anesthesia Division, growing it to over $300 million in revenue. More recently, Dr. Ramani joined Summit Partners’ Executive-in-Residence program, working with Summit’s Healthcare & Life Sciences team to identify new investment opportunities within growth-stage healthcare companies, as well as to evaluate prospects of current investments. In connection with that appointment, he was named CEO of portfolio company, MedOptions, Inc., the nation's largest behavioral health services provider to post-acute care facilities.
In addition to Anesthetix, Dr. Ramani, a former practicing anesthesiologist and interventional pain management specialist, also co-developed several other companies providing anesthesia-related services, including a full-service healthcare staffing firm and an anesthesia revenue cycle management company. He attended Jefferson Medical College in Philadelphia, interned at Morristown Memorial Hospital, and completed residency in Anesthesiology and Interventional Pain Management at Mount Sinai Medical School, New York.
Dr. Ramani commented: "As a physician myself and as a veteran executive of the healthcare services industry, I have long been aware of and admired CRH's unique position in the marketplace. As a supplier of critical and valuable services to gastroenterologists and their patients, CRH is well positioned to rapidly grow its footprint in its core services, expand its offerings, and be an even more useful partner to its customers. I am excited to take the helm at this important point in the company's development, and look forward to working with the top-flight team in place and exploring the opportunities in front of us."
Dr. Ramani will be based in the United States, reflecting the geographic concentration of the Company’s current operations. Mr. Wright has agreed to assist as necessary to ensure an orderly transition.
VANCOUVER, B.C. – April 9, 2019 –
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (“CRH” or the “Company”), today announced the appointment of Dr. Tushar Ramani as CEO of the Company, replacing outgoing CEO Edward Wright. Dr. Ramani, a 30 year veteran of the anesthesia industry, will also join the Company’s board as a director, in place of Mr. Wright.
“We would like first to thank Edward Wright for his long service and for leading the transformation of the Company into the gastrointestinal anesthesia business” commented Dr. Anthony Holler, Chairman of the Board of the Company. “While we have enjoyed tremendous growth, the Board of Directors believes it is time to take the next step in our development and we believe Tushar is the perfect executive to lead us. Tushar brings extensive experience in both managing and providing healthcare services, growing companies and creating shareholder value.”
Dr. Ramani was a co-founder and president of Anesthetix Management, LLC, a national provider of comprehensive anesthesiology and pain management solutions to hospitals and surgery centers, which was acquired by TeamHealth Holdings, Inc., a physician services organization listed on the NYSE at that time. Dr. Ramani remained as President of TeamHealth's Anesthesia Division, growing it to over $300 million in revenue. More recently, Dr. Ramani joined Summit Partners’ Executive-in-Residence program, working with Summit’s Healthcare & Life Sciences team to identify new investment opportunities within growth-stage healthcare companies, as well as to evaluate prospects of current investments. In connection with that appointment, he was named CEO of portfolio company, MedOptions, Inc., the nation's largest behavioral health services provider to post-acute care facilities.
In addition to Anesthetix, Dr. Ramani, a former practicing anesthesiologist and interventional pain management specialist, also co-developed several other companies providing anesthesia-related services, including a full-service healthcare staffing firm and an anesthesia revenue cycle management company. He attended Jefferson Medical College in Philadelphia, interned at Morristown Memorial Hospital, and completed residency in Anesthesiology and Interventional Pain Management at Mount Sinai Medical School, New York.
Dr. Ramani commented: "As a physician myself and as a veteran executive of the healthcare services industry, I have long been aware of and admired CRH's unique position in the marketplace. As a supplier of critical and valuable services to gastroenterologists and their patients, CRH is well positioned to rapidly grow its footprint in its core services, expand its offerings, and be an even more useful partner to its customers. I am excited to take the helm at this important point in the company's development, and look forward to working with the top-flight team in place and exploring the opportunities in front of us."
Dr. Ramani will be based in the United States, reflecting the geographic concentration of the Company’s current operations. Mr. Wright has agreed to assist as necessary to ensure an orderly transition.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,73 | |
| -0,91 | |
| +0,08 | |
| -0,66 | |
| -0,72 | |
| -0,67 | |
| -1,26 | |
| -1,17 | |
| +4,14 | |
| -3,89 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 237 | ||
| 87 | ||
| 85 | ||
| 83 | ||
| 62 | ||
| 59 | ||
| 56 | ||
| 47 | ||
| 34 | ||
| 34 |
